OVID vs RNGR
OVID: Ovid Therapeutics is a clinical-stage biopharmaceutical company developing differentiated small molecule medicines to address unmet needs in epilepsy and psychiatric disorders by targeting neuronal hyperexcitability. RNGR: Ranger Energy Services provides essential well maintenance and completion-related equipment and services to support oil and natural gas exploration and production.
Side-by-side fundamentals
| Metric | OVID | RNGR | Edge |
|---|---|---|---|
| Price as of 2026-10-30 close | $2.54 | $15.02 | |
| Market cap | $496M | $351M | |
| P/E as of 2026-10-30 | n/a | 25.03 | |
| Net margin FY2025, SEC XBRL | -240.1% | +2.2% | RNGR higher |
| Operating margin FY2025, SEC XBRL | -585.2% | +2.8% | RNGR higher |
| ROE FY2025, SEC XBRL | -13.3% | +4.1% | RNGR higher |
| ROA FY2025, SEC XBRL | -11.5% | +2.9% | RNGR higher |
| Debt / equity 0 — no debt reported, balance sheet 2026-06-30 | 0.00 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +1181.3% | -4.2% | OVID higher |
| Revenue CAGR (3y) SEC XBRL | +69.0% | -3.5% | OVID higher |
| Dividend yield as of 2026-09-02 | n/a | 1.60% | |
| Dividend streak (yrs) SEC XBRL | 0 | 1 | RNGR higher |
| Beta as of 2026-09-02 | 1.53 | 1.03 | |
| 1-year return as of 2026-10-30 close | +85.4% | +8.7% | OVID higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.